SBK001 Receives Epidemic Response Research Funding from Chengdu Hi-Tech Zone

SBK’s independently developed Class 1 chemical novel drug, SBK001, has been selected for funding under the 2020 second batch of the Chengdu Hi-Tech Zone’s Measures to Strengthen Pandemic Prevention Research and Material Support. This recognition highlights the company’s innovative R&D capabilities.